TrialGynecologic oncology2020

Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study.

Krishnansu S Tewari et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.